HER2 -ve
Showing 1 - 25 of >10,000
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients Trial (PERT-IJS plus trastuzumab,
Not yet recruiting
- HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
- PERT-IJS plus trastuzumab, carboplatin and docetaxel
- Perjeta plus trastuzumab, carboplatin and docetaxel
- (no location specified)
Sep 21, 2023
HER2-ve Metastatic Breast Cancer, Germline BRCA1/2 Mutations, Somatic BRCA1/2 Mutations Trial in Worldwide (Olaparib)
Completed
- HER2-ve Metastatic Breast Cancer
- +2 more
-
Towson, Maryland
- +122 more
Dec 22, 2022
Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)
Not yet recruiting
- Breast Cancer
- HER2-positive Breast Cancer
-
São Paulo, BrazilCentro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023
HER2-low in Unresectable and/or Metastatic Breast Cancer
Not yet recruiting
- Breast Neoplasms, Breast Cancer, Breast Carcinoma, Genes, HER-2, Genes, HER2
- (no location specified)
Nov 6, 2023
18F-HER2 PET Trial in Hangzhou (18F-HER2 PET)
Not yet recruiting
- 18F-HER2 PET
- 18F-HER2 PET
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of med
Aug 2, 2023
HER2 Expression and Clinical Pathological Characteristics in
Recruiting
- HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
- Collect HER2 expression in prostate cancer patients
-
Jinan, Shandong, ChinaQilu hospital
Nov 17, 2023
HER2-low in Metastatic Breast Cancer Patients
Not yet recruiting
- HER2-negative
- (no location specified)
Nov 9, 2023
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/
Not yet recruiting
- HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- SHR-A1811
- Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- (no location specified)
Nov 6, 2023
HER2-positive Advanced Breast Cancer Patients Treated With ADC
Recruiting
- Breast Cancer
- HER2 expression of circulating tumor cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Apr 18, 2023
HER2-low Advanced Breast Cancer Patients Treated With ADC
Recruiting
- Breast Cancer
- HER2 expression of circulating tumor cells
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Apr 18, 2023
Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)
Not yet recruiting
- Solid Tumor
- Intravenous infusion anti-HER2-CAR-T cell
-
Shenyang, Liaoning, ChinaPhase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023
Breast Cancer Trial (Trastuzumab Deruxtecan)
Not yet recruiting
- Breast Cancer
- Trastuzumab Deruxtecan
- (no location specified)
Jul 10, 2023
HER2-positive Gastric Cancer, Immunotherapy Trial in Shanghai (Disitamab Vedotin combined with fruquintinib and Tislelizumab)
Recruiting
- HER2-positive Gastric Cancer
- Immunotherapy
- Disitamab Vedotin combined with fruquintinib and Tislelizumab
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Aug 8, 2023
Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer Trial in Boston (Cessation of anti-HER2 treatment)
Not yet recruiting
- Breast Cancer
- +2 more
- Cessation of anti-HER2 treatment
-
Boston, Massachusetts
- +1 more
Feb 9, 2023
Survival Rate of HER2-Low Breast Cancer Patients
Completed
- HER2 Low Breast Carcinoma
- immunohistochemistry (IHC) and in situ hybridization (ISH) Test
- (no location specified)
Mar 2, 2023
HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer Trial in Beijing (KN026, KN046, XELOX)
Not yet recruiting
- HER2-positive Colorectal Cancer
- HER2-positive Biliary Tract Cancer
- KN026
- +2 more
-
Beijing, State*, ChinaPeking University cancer hospital & institution
Aug 2, 2023
HER2 Low Breast Carcinoma Trial (SHR-A1811 for injection)
Not yet recruiting
- HER2 Low Breast Carcinoma
- SHR-A1811 for injection
- (no location specified)
Jun 12, 2023
HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without
Not yet recruiting
- HER2-positive Breast Cancer
- Standard of Care Adjuvant Breast Radiation
- Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
- (no location specified)
Jan 20, 2023
Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2
Recruiting
- HER2-positive Breast Cancer
- Early-stage Breast Cancer
- pyrotinib combined with Capecitabine
- treatment of physician's choice
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Sep 6, 2023
HER2 Positive Advanced Solid Tumors Trial (HypoSti.CAR-HER2 T cells, Albumin-bound paclitaxel, Cyclophosphamide)
Not yet recruiting
- HER2 Positive Advanced Solid Tumors
- HypoSti.CAR-HER2 T cells
- +2 more
- (no location specified)
Jan 12, 2023
HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))
Not yet recruiting
- HER2-positive Breast Cancer
- Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
- (no location specified)
Jul 20, 2023
DESTINY Breast Respond HER2-low Europe
Not yet recruiting
- Unresectable Breast Cancer
- +2 more
- Trastuzumab deruxtecan
- (no location specified)
Jul 6, 2023
HER2-Positive Cancer Trial in Wuhan
Active, not recruiting
- HER2-Positive Cancer
-
Wuhan, Hubei, ChinaTongjiHospital
Sep 7, 2022
HER2-HER3 Dimer in Tumour and Blood Samples From HER2 Positive
Recruiting
- HER2-positive Breast Cancer
- Acquisition of blood samples and tumour tissue samples (biopsies)
-
Brighton, United Kingdom
- +1 more
Nov 9, 2022
HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)
Not yet recruiting
- HR+/HER2-breast Cancer
- Standard endocrine therapy plus Apatinib
- (no location specified)
Jun 2, 2023